Mark Moody, PhD
Mark Moody brings more than 30 years of industry experience in multiple areas of drug development, including process/analytical development, manufacturing, toxicology, regulatory, and clinical development. Prior to Activate, Mark served in a variety of roles at Merrimack Pharmaceuticals, including Vice President of Manufacturing and Vice President of Analytical Science, where he provided strategic guidance and tactical management for activities required for the cGMP manufacturing and analysis of Merrimack’s portfolio of biologic and nano-liposome products, including Onivyde, a liposomal formulation of irinotecan approved for pancreatic cancer. In addition to his role at Activate, he is the COO of Immunova LLC (the parent company of Activate), a member of the Board of Directors and Scientific Advisor for Saugatuck Therapeutics Ltd, and a member of the Management Committee of Skinosive, SAS.
Mark was trained as a Postdoctoral Fellow in the Department of Microbiology and Immunology at Duke University, and earned his Ph.D. in the Department of Microbiology at the University of Georgia.